Salute e Benessere
Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Each year, Frost & Sullivan presents this honor to a company that demonstrates outstanding strategy development and implementation. It celebrates forward-looking organizations that are redefining their industries through transformative innovation and growth excellence. Viva Biotech stood out in the rigorous benchmarking, excelling in both strategy effectiveness and execution.
" " said Priyanka Jain , senior research analyst at Frost & Sullivan.
Innovation is central to Viva Biotech's philosophy. Its AI-Driven Drug Discovery (AIDD) platform comprising V-Scepter, V-Orb, and V-Mantle modules, addresses longstanding drug design challenges with the combination of predictive modeling, physics-based simulations, and generative AI. These tools are directly integrated with wet lab experimentation, allowing for rapid validation and iterative refinement of drug candidates.
By combining AIDD and SBDD in a unified workflow, Viva Biotech has built an integrated platform that has supported more than projects for ove global clients. The platform enables faster discovery, up to cost savings, and consistently high success rates across a broad range of targets, including challenging ones. These advantages allow partners to advance preclinical programs with greater efficiency and accelerate the delivery of innovative therapies.
Viva Biotech has demonstrated remarkable agility in adapting to the evolving pharmaceutical research landscape. The company's investment in AI-driven modeling, structure-based drug discovery, and seamless lab-in-the-loop systems has enabled it to accelerate decision-making and support first-in-class programs for clients worldwide.
This recognition also resonates with Viva Biotech's long-term vision. " "said Dr.
Derek Ren , CEO of Viva Biotech ( Shanghai ) Ltd.. " "
Read Frost & Sullivan's full recognition and analysis: https://www.frost.com/wp-content/uploads/2025/09/Viva-Biotech_Writeup.pdf
Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.
Logo - https://mma.prnewswire.com/media/2784195/5535043/Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/viva-biotech-receives-frost--sullivans-2025-apac-technology-innovation-leadership-recognition-in-the-integrated-intelligent-drug-discovery-industry-302569339.html